exhibit991

Corporate | 3 August 2023 22:03 EQS-News: MorphoSys AG / Key word(s): Half Year Results Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023 03.08.2023 / 22:03 CET/CEST The issuer is solely responsible for the content of this announcement. Conference Call Alert Planegg/Munich, Germany, August 03, 2023 Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023 MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the second quarter and first half 2023 on August 09, 2023, at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT). MorphoSys’ Management team will host a conference call and webcast on August 10, 2023, at 02:00 pm CEST (01:00 pm BST; 08:00 am EDT) to present the results for the second quarter and first half 2023 and provide an outlook for 2023. The conference call will start with a presentation by the Management team followed by a Q&A session. A live webcast and slides will be made available at the Investors section on MorphoSys’ website, www.morphosys.com. To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website: https://services.choruscall.it/DiamondPassRegistration/register? confirmationNumber=1920288&linkSecurityString=29d59d300 Please dial in 10 minutes before the beginning of the conference. A replay of the conference will also be available at the corporate website following the live event. MorphoSys AG Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023

About MorphoSys At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter and LinkedIn. Forward Looking Statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys’ results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys’ expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys’ reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys’ Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. For more information, please contact: Media Contacts: Thomas Biegi Vice President Investor Contacts: Dr. Julia Neugebauer Head of Investor Relations

03.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com Language: English Company: MorphoSys AG Semmelweisstr. 7 82152 Planegg Germany Phone: +49 (0)89 899 27-0 Fax: +49 (0)89 899 27-222 E-mail: investors@morphosys.com Internet: www.morphosys.com ISIN: DE0006632003 WKN: 663200 Indices: SDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Tel.: +49 (0)89 / 89927 26079 thomas.biegi@morphosys.com Tel: +49 (0)89 / 899 27 179 julia.neugebauer@morphosys.com Eamonn Nolan Director Tel: +1 617-548-9271 eamonn.nolan@morphosys.com

Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq EQS News ID: 1695583 End of News EQS News Service